What is the clinical evidence from this study?

Study design: Review. Population: Atrial fibrillation. Intervention: Atrial selective antiarrhythmic agents.

January 1, 2009Cardiovascular & Hematological Agents in Medicinal Chemistry

Antiarrhythmic Drug Therapy for Atrial Fibrillation: Focus on Atrial Selectivity and Safety

View Full Paper

Ask AI

Bookmark

Key result

Atrial-selective antiarrhythmic agents, such as IKur and IKACh blockers, are being evaluated as potentially safer rhythm control therapies for atrial fibrillation.

Population

Patients with atrial fibrillation

Design

Review

Authors

DLDanhui LiHebei Agricultural University HSHsin‐Yun SunNational Taiwan University PLPaul LévesqueBristol-Myers Squibb (Germany)

Discussion

Member takes

Implication

May support atrial-selective antiarrhythmic development; leaves open clinical adoption pending further randomized trials.

Structured PICO

Population

Patients with atrial fibrillation

Intervention

Atrial selective antiarrhythmic agents (including IKur blockers, IKACh blockers, gap junction modulators, and angiotensin-converting enzyme inhibitors)

Outcome

Prevention and treatment of atrial fibrillation with improved safety profile (avoidance of ventricular proarrhythmia)

Novel atrial-selective antiarrhythmic agents targeting specific ion channels like IKur and IKACh offer a promising strategy for safer rhythm control in atrial fibrillation by avoiding ventricular proarrhythmia.

Limitations

Human experience with IKur-blockers is limited.
No drugs have been shown to have pure selectivity for the IKACh current.

Cite This Study

Li et al. (2009) conducted a review in Atrial fibrillation. Atrial selective antiarrhythmic agents was evaluated. Atrial-selective antiarrhythmic agents, such as IKur and IKACh blockers, are being evaluated as potentially safer rhythm control therapies for atrial fibrillation.

synapsesocial.com/papers/6a557f3dcae1d55e053ea930 https://doi.org/10.2174/187152509787047621

Topics

Persistent AF management Atrial fibrillation Anticoagulation in AF AF ablation outcomes

View Full Paper

Ask AI

Bookmark

Antiarrhythmic Drug Therapy for Atrial Fibrillation: Focus on Atrial Selectivity and Safety

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Topics

Antiarrhythmic Drug Therapy for Atrial Fibrillation: Focus on Atrial Selectivity and Safety

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Also Consider

Topics

Also Consider